RxDoctor Payments Data

Barbara Fardo, DO

Family Medicine · Cranberry Twp, PANPI 1902890270

Payments from drug & device makers

$13,089in general payments, 2019–2025

Across 870 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • GSK$1K
  • AstraZeneca$967
  • Amgen$609
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$1001%
  • Food & beverage$12,71097%
  • Education$2322%
  • Gifts$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk125$1,745
AbbVie(2 entities)116$1,720
Pfizer100$1,209
GSK83$1,136
AstraZeneca56$967
Amgen(2 entities)38$609
Lilly USA, LLC35$530
Boehringer Ingelheim33$484
Johnson & Johnson32$455
Merck25$408
Abbott17$313
Amarin Pharma, Inc.20$304
Currax Pharmaceuticals LLC17$259
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$252
Bayer15$244
Takeda Pharmaceuticals U.S.A., Inc.24$242
E.r. Squibb & Sons, L.L.C.13$189
Astellas Pharma US Inc6$187
Daiichi Sankyo Inc.7$139
Comsort, Inc1$100
Phathom Pharmaceuticals, Inc.6$94
Biohaven Pharmaceuticals, Inc.5$85
Exact Sciences4$76
Sanofi-aventis U.S. LLC5$73
Esperion Therapeutics, Inc.4$71
Grifols USA, LLC3$70
Sanofi Pasteur Inc.4$65
Biohaven Pharmaceutical Holding Company Ltd.3$59
Inari Medical, Inc.2$57
Ironwood Pharmaceuticals, Inc3$52
Shield Therapeutics Inc3$52
Sumitomo Pharma America, Inc.3$50
Tosoh Bioscience, Inc.1$47
Cequr Corporation2$46
Genentech USA, Inc.3$44
Kowa Pharmaceuticals America, Inc.3$43
CSL Behring2$41
Teva Pharmaceuticals USA, Inc.3$40
Vivus LLC3$40
Eisai Inc.3$38
Mylan Specialty L.p.2$36
Medicomp Inc2$34
Kaleo, Inc.2$31
Biogen2$30
Melinta Therapeutics, LLC2$29
Upsher-smith Laboratories LLC1$25
Axsome Therapeutics, Inc.1$25
Photonicare Inc1$23
Vertex1$23
Organogenesis Inc.1$22
Novartis1$20
Otsuka America Pharmaceutical, Inc.1$19
Amneal Pharmaceuticals LLC1$19
Shire North American Group Inc1$18
Ultragenyx Pharmaceutical Inc.1$18
Aytu Biopharma, Inc.1$16
Verona Pharma, Inc.1$15
Dermira, Inc.1$14
Paratek Pharmaceuticals, Inc.1$14
Radius Health, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,089 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$191,366
Medicare patients
369
Services billed
4,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$188,910
JardianceEmpagliflozin83$95,638
FarxigaDapagliflozin Propanediol59$82,080
OzempicSemaglutide64$75,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$59,552
XareltoRivaroxaban54$58,003
MounjaroTirzepatide40$42,416
SynjardyEmpagliflozin/Metformin Hcl32$33,416
RybelsusSemaglutide12$23,032
TrulicityDulaglutide16$21,249
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$16,576
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$16,159
MyrbetriqMirabegron25$15,813
TradjentaLinagliptin17$15,602
LinzessLinaclotide23$13,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,209$188,910192 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$484$144,656132 claims
Novo NordiskOzempic, Rybelsus$1,745$98,39476 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$1,136$90,035117 claims
AstraZenecaFarxiga$967$82,08059 claims
Lilly USA, LLCMounjaro, Trulicity$530$63,66556 claims
Johnson & JohnsonXarelto$455$58,00354 claims
AbbVieLinzess, Synthroid$1,720$19,599109 claims
Astellas Pharma US IncMyrbetriq$187$15,81325 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$6,275427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Cranberry Twp

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →